CureVac CEO on IPO Pricing, Covid-19 Vaccine, Partners

Aug.14 — CureVac Chief Executive Officer at Franz-Werner Haas discusses the company’s $213 million initial public offering, partnerships on Covid-19 vaccine development, and, and updates progress on their phase one coronavirus vaccine trial . He speaks on "Bloomberg Markets: European Close."

Watch the video at Bloomberg – Corona Outbreak